Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes
Mirko V Sikirica,1 Alan A Martin,2 Robert Wood,3 Andrea Leith,3 James Piercy,3 Victoria Higgins3 1Value Evidence and Outcomes, GlaxoSmithKline, Collegeville, PA, USA; 2Value Evidence and Outcomes, GlaxoSmithKline, London, UK; 3Diabetes, Adelphi Real World, Bollington, Cheshire, UK Aim: Nonadherence...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2017-09-01
|
| Series: | Diabetes, Metabolic Syndrome and Obesity |
| Subjects: | |
| Online Access: | https://www.dovepress.com/reasons-for-discontinuation-of-glp1-receptor-agonists-data-from-a-real-peer-reviewed-article-DMSO |
| _version_ | 1828046320566272000 |
|---|---|
| author | Sikirica MV Martin AA Wood R Leith A Piercy J Higgins V |
| author_facet | Sikirica MV Martin AA Wood R Leith A Piercy J Higgins V |
| author_sort | Sikirica MV |
| collection | DOAJ |
| description | Mirko V Sikirica,1 Alan A Martin,2 Robert Wood,3 Andrea Leith,3 James Piercy,3 Victoria Higgins3 1Value Evidence and Outcomes, GlaxoSmithKline, Collegeville, PA, USA; 2Value Evidence and Outcomes, GlaxoSmithKline, London, UK; 3Diabetes, Adelphi Real World, Bollington, Cheshire, UK Aim: Nonadherence to glucagon-like peptide-1 receptor agonists (GLP1 RAs) is relatively common among patients with type 2 diabetes mellitus (T2DM). This study sought to identify reasons why patients discontinue GLP1 RAs.Materials and methods: Retrospective data from the Adelphi Diabetes Disease Specific Programme were used. Physicians managing patients with T2DM were surveyed via face-to-face interviews, and patients treated for T2DM were surveyed via self-completed questionnaires. Patient data were stratified by current versus prior GLP1 RA use.Results: Physicians (n=443) most frequently reported inadequate blood glucose control (45.6%), nausea/vomiting (43.8%), and gastrointestinal (GI) side effects (36.8%) as reasons for GLP1 RA discontinuation. Patients (n=194) reported the GI-related issues “Made me feel sick” (64.4%) and “Made me throw up” (45.4%) as their top reasons for discontinuation. The most common problems reported (excluding cost) for those currently using GLP1 RAs were “Prefer oral medication over injections” (patients 56%, physicians 32.6%), “Made me feel sick” (patients 38.1%, physicians 16.3%), and “Did not help lose weight” (patients 25.4%, physicians 18%). The most bothersome problems for patients globally (frequency reporting very/extremely bothersome) (excluding cost) were “Difficult to plan meals around” (55.6%), “Made me throw up” (51.6%), and “Caused weight gain” (50%).Conclusion: Both patients and physicians reported GI-related issues as a prominent factor, but disparities between patient experiences and physician perceptions were revealed, suggesting gaps in physician–patient communication. Understanding patients’ expectations of GLP1 RAs and physicians’ patient-management practices may help increase GLP1 RA adherence and thereby potentially enhance diabetes care. Keywords: antidiabetic drug, cross-sectional survey, discontinuation, incretins, incretin therapy, glycemic control |
| first_indexed | 2024-04-10T18:24:11Z |
| format | Article |
| id | doaj.art-202a3453a4724bdbaf304549fd75661f |
| institution | Directory Open Access Journal |
| issn | 1178-7007 |
| language | English |
| last_indexed | 2024-04-10T18:24:11Z |
| publishDate | 2017-09-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Diabetes, Metabolic Syndrome and Obesity |
| spelling | doaj.art-202a3453a4724bdbaf304549fd75661f2023-02-02T06:05:30ZengDove Medical PressDiabetes, Metabolic Syndrome and Obesity1178-70072017-09-01Volume 1040341234960Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetesSikirica MVMartin AAWood RLeith APiercy JHiggins VMirko V Sikirica,1 Alan A Martin,2 Robert Wood,3 Andrea Leith,3 James Piercy,3 Victoria Higgins3 1Value Evidence and Outcomes, GlaxoSmithKline, Collegeville, PA, USA; 2Value Evidence and Outcomes, GlaxoSmithKline, London, UK; 3Diabetes, Adelphi Real World, Bollington, Cheshire, UK Aim: Nonadherence to glucagon-like peptide-1 receptor agonists (GLP1 RAs) is relatively common among patients with type 2 diabetes mellitus (T2DM). This study sought to identify reasons why patients discontinue GLP1 RAs.Materials and methods: Retrospective data from the Adelphi Diabetes Disease Specific Programme were used. Physicians managing patients with T2DM were surveyed via face-to-face interviews, and patients treated for T2DM were surveyed via self-completed questionnaires. Patient data were stratified by current versus prior GLP1 RA use.Results: Physicians (n=443) most frequently reported inadequate blood glucose control (45.6%), nausea/vomiting (43.8%), and gastrointestinal (GI) side effects (36.8%) as reasons for GLP1 RA discontinuation. Patients (n=194) reported the GI-related issues “Made me feel sick” (64.4%) and “Made me throw up” (45.4%) as their top reasons for discontinuation. The most common problems reported (excluding cost) for those currently using GLP1 RAs were “Prefer oral medication over injections” (patients 56%, physicians 32.6%), “Made me feel sick” (patients 38.1%, physicians 16.3%), and “Did not help lose weight” (patients 25.4%, physicians 18%). The most bothersome problems for patients globally (frequency reporting very/extremely bothersome) (excluding cost) were “Difficult to plan meals around” (55.6%), “Made me throw up” (51.6%), and “Caused weight gain” (50%).Conclusion: Both patients and physicians reported GI-related issues as a prominent factor, but disparities between patient experiences and physician perceptions were revealed, suggesting gaps in physician–patient communication. Understanding patients’ expectations of GLP1 RAs and physicians’ patient-management practices may help increase GLP1 RA adherence and thereby potentially enhance diabetes care. Keywords: antidiabetic drug, cross-sectional survey, discontinuation, incretins, incretin therapy, glycemic controlhttps://www.dovepress.com/reasons-for-discontinuation-of-glp1-receptor-agonists-data-from-a-real-peer-reviewed-article-DMSOantidiabetic drugcross-sectional surveydiscontinuationincretinsincretin therapyglycemic control |
| spellingShingle | Sikirica MV Martin AA Wood R Leith A Piercy J Higgins V Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes Diabetes, Metabolic Syndrome and Obesity antidiabetic drug cross-sectional survey discontinuation incretins incretin therapy glycemic control |
| title | Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes |
| title_full | Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes |
| title_fullStr | Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes |
| title_full_unstemmed | Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes |
| title_short | Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes |
| title_sort | reasons for discontinuation of glp1 receptor agonists data from a real world cross sectional survey of physicians and their patients with type 2 diabetes |
| topic | antidiabetic drug cross-sectional survey discontinuation incretins incretin therapy glycemic control |
| url | https://www.dovepress.com/reasons-for-discontinuation-of-glp1-receptor-agonists-data-from-a-real-peer-reviewed-article-DMSO |
| work_keys_str_mv | AT sikiricamv reasonsfordiscontinuationofglp1receptoragonistsdatafromarealworldcrosssectionalsurveyofphysiciansandtheirpatientswithtype2diabetes AT martinaa reasonsfordiscontinuationofglp1receptoragonistsdatafromarealworldcrosssectionalsurveyofphysiciansandtheirpatientswithtype2diabetes AT woodr reasonsfordiscontinuationofglp1receptoragonistsdatafromarealworldcrosssectionalsurveyofphysiciansandtheirpatientswithtype2diabetes AT leitha reasonsfordiscontinuationofglp1receptoragonistsdatafromarealworldcrosssectionalsurveyofphysiciansandtheirpatientswithtype2diabetes AT piercyj reasonsfordiscontinuationofglp1receptoragonistsdatafromarealworldcrosssectionalsurveyofphysiciansandtheirpatientswithtype2diabetes AT higginsv reasonsfordiscontinuationofglp1receptoragonistsdatafromarealworldcrosssectionalsurveyofphysiciansandtheirpatientswithtype2diabetes |